379P - Concurrent chemoradiotherapy with daily low-dose carboplatin for early laryngeal cancers (T1b/T2): A retrospective analysis

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Head and Neck Cancers
Surgical Oncology
Presenter Tetsuro Wakasugi
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors T. Wakasugi, H. Suzuki
  • Otorhinolaryngology-head And Neck Surgery, University of Occupational and Environmental Health, 807-8555 - Kitakyushu/JP



The goals of treatment for laryngeal cancer are cure and preservation of the larynx. For organ preservation, radiotherapy or surgery alone might be insufficient. This study investigated the efficacy and safety of concurrent chemoradiotherapy with daily low-dose carboplatin for early laryngeal cancer.


We reviewed the clinical records of 50 patients with early laryngeal cancer treated at our institute between October 2005 and December 2015. Treatment was radiotherapy at 64.8-72.0 Gy in 54-60 fractions (1.2 Gy/fraction, 2 fractions/day) plus carboplatin (25 mg/m2/day, 5 days/week during radiotherapy). Median age was 66 years (range, 40-87 years). Performance status was 0/1/2 in 26/22/2 patients, tumor site was supraglottic larynx/glottis/subglottic larynx in 11/37/2, T-stage was 1b/2 in 8/42, and N-stage was 0/1/2a/2b in 47/1/0/2.


Full-dose radiotherapy was delivered to all patients. Median total carboplatin dose was 1000 mg/body and median number of carboplatin infusions was 27 (range, 7-32). The overall response rate was 100%. After median follow-up of 44 months (range, 2-117 months), 6 patients showed disease progression and underwent salvage surgery, and 1 patient died due to laryngeal carcinoma. Five-year local failure rates in T1b+T2 and T2 were 16.5% and 19.3%, respectively. Five-year overall survival rates in T1b+T2 and T2 were 93.4% and 92.3%, respectively. No significant difference in overall survival was seen between patients over and under 65 years. No patients required use of a feeding tube or tracheostomy during treatment. The most common grade 3 or 4 adverse events were leucopenia (44%), neutropenia (34%), thrombocytopenia (10%), febrile neutropenia (2%) and mucositis (4%).


Concurrent chemoradiotherapy with daily low-dose carboplatin was safe and offered high local control and survival rates for early laryngeal carcinoma, regardless of age. This treatment is one option for early laryngeal cancer patients who hope to achieve preservation of the larynx.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.